Feb. 11 (Bloomberg) -- Novo Nordisk A/S Chief Executive Officer Lars Rebien Soerensen discusses the U.S. Food and Drug Administration's decision not to approve the insulin maker's Tresiba diabetes treatment, saying more data on heart safety is needed.
He talks from Copenhagen with Francine Lacqua on Bloomberg Television's "On the Move." (Source: Bloomberg)
Shipping Industry Sounding the Alarm on Global Growth
16:40 - If the Baltic Dry Index is any guide for the global economy, the picture is looking stormy. It's plunged to historic lows since the start of the year. Bloomberg looks at why, and what it could tell us about future growth.
Maersk CEO Sees Some Pick-Up In Oil Price By Year End
Heineken Meets Profits Estimates
Will the Fed Continue Hiking?
Please upgrade your Browser
Your browser is out-of-date. Please download one of these excellent browsers: